Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
Status:
Completed
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to determine the antiviral efficacy, safety, and
tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with
chronic genotype 1 or 2 HCV infection who are coinfected with HBV in Taiwan.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir